It is with a deep sense of sadness and loss that we report the sudden and untimely passing of Canthera Discovery Chair, Dr Peter Woodgate, over the Christmas period. The staff and Board of Directors...
A drug discovered by Cancer Therapeutics CRC scientists has entered Phase 2 clinical trials. Amplia Therapeutics Limited recently announced the recruitment of the first patient to the AC...
Canthera Discovery is delighted to announce that its predecessor, Cancer Therapeutics CRC, received the Cooperative Research Australia (CRA) Excellence in Innovation Award for Research Commercialisati...
Cancer Therapeutics has today unveiled its new name and brand identity - Canthera Discovery. This transformation forms part of a wider organisational strategy to continue the incredible legacy of...
Canthera Discovery, a proud member of the Australian Lead Identification Consortium (ALIDC), is delighted to share news of the completion of the purpose-built Australian Drug Discovery Library (ADDL),...
A second discovery out of Cancer Therapeutics CRC has entered into clinical trials. If successful the discovery could be used to treat breast, prostate and lung cancers. The discovery centres aroun...